Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.77 |
| ▸ | ESR1 | P03372 | 6/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2089187 | 0.99 | HRH3 (0.75) | HRH3ESR1KDM4EALDH1A1KMT2A | |
| SCHEMBL19172409 | 0.93 | HRH3 (0.71) | HRH3ESR1KDM4E | |
| SCHEMBL2741672 | 0.93 | HRH3 (0.71) | HRH3ESR1KDM4E | |
| SCHEMBL18595108 | 0.93 | HRH3 (0.71) | HRH3ESR1KDM4E | |
| SCHEMBL18265845 | 0.93 | HRH3 (0.71) | HRH3ESR1KDM4E | |
| Hydrochloric Acid SCHEMBL224629 | 0.92 | HRH3 (0.70) | HRH3ESR1KDM4E | |
| SCHEMBL9942403 | 0.92 | HRH3 (0.69) | HRH3ESR1KDM4EKMT2A | |
| SCHEMBL11805320 | 0.90 | HRH3 (0.71) | HRH3ESR1KDM4EALDH1A1KMT2A | |
| SCHEMBL11808821 | 0.90 | HRH3 (0.71) | HRH3ESR1KDM4EALDH1A1KMT2A | |
| SCHEMBL11808005 | 0.89 | HRH3 (0.69) | HRH3ESR1KDM4EALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080161331-A1 | Compounds Comprising an Oxazoline or Thiazoline Moiety, Processes for Making Them, and Their Uses | UCB PHARMA, S.A. (BE) | 2008-07-03 | — | — | US | claimed |
| EP-1866294-A1 | COMPOUNDS COMPRISING AN OXAZOLINE OR THIAZOLINE MOIETY, PROCESSES FOR MAKING THEM, AND THEIR USES | UCB Pharma, S.A. (BE) | 2007-12-19 | — | — | EP | claimed |
| WO-2006103057-A1 | COMPOUNDS COMPRISING AN OXAZOLINE OR THIAZOLINE MOIETY, PROCESSES FOR MAKING THEM, AND THEIR USES | UCB PHARMA, S.A. (BE) | 2006-10-05 | — | — | WO | claimed |
| US-7863450-B2 | Compounds comprising an oxazoline or thiazoline moiety, processes for making them, and their uses | UCB PHARMA, S.A. (BE) | 2011-01-04 | — | — | US | disclosed |
| US-20080161331-A1 | Compounds Comprising an Oxazoline or Thiazoline Moiety, Processes for Making Them, and Their Uses | UCB PHARMA, S.A. (BE) | 2008-07-03 | — | — | US | disclosed |
| EP-1866294-A1 | COMPOUNDS COMPRISING AN OXAZOLINE OR THIAZOLINE MOIETY, PROCESSES FOR MAKING THEM, AND THEIR USES | UCB Pharma, S.A. (BE) | 2007-12-19 | — | — | EP | disclosed |
| WO-2006103057-A1 | COMPOUNDS COMPRISING AN OXAZOLINE OR THIAZOLINE MOIETY, PROCESSES FOR MAKING THEM, AND THEIR USES | UCB PHARMA, S.A. (BE) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161331-A1 | Compounds Comprising an Oxazoline or Thiazoline Moiety, Processes for Making Them, and Their Uses | NR1H3, NR1I3, NR1I2 | HRH3 196/4885ESR1 172/4885KDM4E 3442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.